Radiation plus chemoimmunotherapy for gastroesophageal junction cancer
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adenocarcinoma cancer at the junction of the stomach and esophagus that has not spread to distant organs.
- You have not had any prior treatment for this cancer.
- You are 18 years or older and able to care for yourself (ECOG 0 or 1).
- Your heart, liver, kidneys, and blood counts are working well enough based on recent tests.
- You do not have an active autoimmune disease, uncontrolled infection, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.